Page 1 | Search Results | Blood Advances | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Validation of the Revised 2022 European LeukemiaNet Risk Stratification in Adult Patients with Acute Myeloid Leukemia

Leo Ruhnke, Marius Bill, Sven Zukunft, Jan-Niklas Eckardt, Silvia Schäfer, Sebastian Stasik, Maher Hanoun, Thomas Schroeder, Lars Fransecky, Björn Steffen, Stefan W Krause, Sebastian Scholl, Andreas Hochhaus, Tim Sauer, Sabrina Kraus, Kerstin Schäfer-Eckart, Martin Kaufmann, Edgar Jost, Tim H. Brümmendorf, Christoph Schliemann, Jan-Henrik Mikesch, Utz Krug, Mathias Hänel, Anke Morgner, Markus Schaich, Andreas Neubauer, Roland Repp, Dirk Niemann, Ruth Seggewiss-Bernhardt, Achim Meinhardt, Johannes Kullmer, Ulrich Kaiser, Wolfgang Blau, Alexander Kiani, Götz Ulrich Grigoleit, Aristoteles Giagounidis, Alexander Arthur Wurm, Heidi Altmann, Jan Moritz M Middeke, Johannes Schetelig, Carsten Müller-Tidow, Friedrich Stölzel, Claudia D. Baldus, Uwe Platzbecker, Hubert Serve, Martin Bornhäuser, Christian Thiede, Christoph Röllig

Blood Adv bloodadvances.2024013304.

https://doi.org/10.1182/bloodadvances.2024013304

Published: 2024

Includes: Supplemental data

Journal Articles

Teclistamab impairs detection of BCMA CAR-T cells

Bettina Glatte, Kerstin Wenk, Anja Grahnert, Maik Friedrich, Maximilian Merz, Vladan Vucinic, Luise Fischer, Kristin Reiche, Miriam Alb, Michael Hudecek, Paul Franz, Stephan Fricke, Uwe Platzbecker, Ulrike Koehl, Ulrich Sack, Andreas Boldt, Sunna Hauschildt, Ronald Weiss

Blood Adv (2023) 7 (15): 3842–3845.

https://doi.org/10.1182/bloodadvances.2023009714

Published: 2023

Includes: Supplemental data

Journal Articles

Momelotinib long-term safety and survival in myelofibrosis: integrated analysis of phase 3 randomized controlled trials

Blood Adv (2023) 7 (14): 3582–3591.

https://doi.org/10.1182/bloodadvances.2022009311

Published: 2023

Includes: Supplemental data

Journal Articles

An agenda to advance research in myelodysplastic syndromes: a TOP 10 priority list from the first international workshop in MDS

Maximilian Stahl, Omar Abdel-Wahab, Andrew H. Wei, Michael R. Savona, Mina L. Xu, Zhuoer Xie, Justin Taylor, Daniel Starczynowski, Guillermo F. Sanz, David A. Sallman, Valeria Santini, Gail J. Roboz, Mrinal M. Patnaik, Eric Padron, Olatoyosi Odenike, Aziz Nazha, Stephen D. Nimer, Ravindra Majeti, Richard F. Little, Steven Gore, Alan F. List, Vijay Kutchroo, Rami S. Komrokji, Tae Kon Kim, Nina Kim, Christopher S. Hourigan, Robert P. Hasserjian, Stephanie Halene, Elizabeth A. Griffiths, Peter L. Greenberg, Maria Figueroa, Pierre Fenaux, Fabio Efficace, Amy E. DeZern, Matteo G. Della Porta, Naval G. Daver, Jane E. Churpek, Hetty E. Carraway, Andrew M. Brunner, Uma Borate, John M. Bennett, Rafael Bejar, Jacqueline Boultwood, Sanam Loghavi, Jan Philipp Bewersdorf, Uwe Platzbecker, David P. Steensma, Mikkael A. Sekeres, Rena J. Buckstein, Amer M. Zeidan

Blood Adv (2023) 7 (12): 2709–2714.

https://doi.org/10.1182/bloodadvances.2022008747

Published: 2023

Journal Articles

Impact of IDH1 and IDH2 mutation detection at diagnosis and in remission in patients with AML receiving allogeneic transplantation

Marius Bill, Madlen Jentzsch, Lara Bischof, Jessica Kohlschmidt, Juliane Grimm, Laura Katharina Schmalbrock, Donata Backhaus, Dominic Brauer, Karoline Goldmann, Georg-Nikolaus Franke, Vladan Vucinic, Dietger Niederwieser, Alice S. Mims, Uwe Platzbecker, Ann-Kathrin Eisfeld, Sebastian Schwind

Blood Adv (2023) 7 (3): 436–444.

https://doi.org/10.1182/bloodadvances.2021005789

Published: 2023

Includes: Supplemental data

Journal Articles

Efficacy and safety of avapritinib in previously treated patients with advanced systemic mastocytosis

Andreas Reiter, Juliana Schwaab, Daniel J. DeAngelo, Jason Gotlib, Michael W. Deininger, Kristen M. Pettit, Iván Alvarez-Twose, Alessandro M. Vannucchi, Jens Panse, Uwe Platzbecker, Olivier Hermine, Ingunn Dybedal, Hui-Min Lin, Svetlana N. Rylova, Katrin Ehlert, Saša Dimitrijević, Deepti H. Radia

Blood Adv (2022) 6 (21): 5750–5762.

https://doi.org/10.1182/bloodadvances.2022007539

Published: 2022

Includes: Supplemental data

Journal Articles

Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML

Lionel Adès, Larisa Girshova, Vadim A. Doronin, María Díez-Campelo, David Valcárcel, Suman Kambhampati, Nora-Athina Viniou, Dariusz Woszczyk, Raquel De Paz Arias, Argiris Symeonidis, Achilles Anagnostopoulos, Eduardo Ciliao Munhoz, Uwe Platzbecker, Valeria Santini, Robert J. Fram, Ying Yuan, Sharon Friedlander, Douglas V. Faller, Mikkael A. Sekeres

Blood Adv (2022) 6 (17): 5132–5145.

https://doi.org/10.1182/bloodadvances.2022007334

Published: 2022

Includes: Supplemental data

Journal Articles

Impact of MRD status in patients with AML undergoing allogeneic stem cell transplantation in the first vs the second remission

Madlen Jentzsch, Lara Bischof, Donata Backhaus, Dominic Brauer, Julia Schulz, Georg-Nikolaus Franke, Vladan Vucinic, Dietger Niederwieser, Uwe Platzbecker, Sebastian Schwind

Blood Adv (2022) 6 (15): 4570–4580.

https://doi.org/10.1182/bloodadvances.2022007168

Published: 2022

Includes: Supplemental data

Journal Articles

Deep sequencing in CD34 + cells from peripheral blood enables sensitive detection of measurable residual disease in AML

Sebastian Stasik, Clara Burkhard-Meier, Michael Kramer, Jan M. Middeke, Uta Oelschlaegel, Katja Sockel, Gerhard Ehninger, Hubert Serve, Carsten Müller-Tidow, Claudia D. Baldus, Christoph Röllig, Martin Bornhäuser, Uwe Platzbecker, Christian Thiede

Blood Adv (2022) 6 (11): 3294–3303.

https://doi.org/10.1182/bloodadvances.2021006233

Published: 2022

Includes: Supplemental data

Journal Articles

Differential impact of IDH1 / 2 mutational subclasses on outcome in adult AML: results from a large multicenter study

Blood Adv (2022) 6 (5): 1394–1405.

https://doi.org/10.1182/bloodadvances.2021004934

Published: 2022

Includes: Supplemental data

Journal Articles

The diagnostic red blood cell distribution width as a prognostic factor in acute myeloid leukemia

Vladan Vucinic, Leo Ruhnke, Katja Sockel, Maximilian Alexander Röhnert, Donata Backhaus, Dominic Brauer, Georg-Nikolaus Franke, Dietger Niederwieser, Martin Bornhäuser, Christoph Röllig, Uwe Platzbecker, Sebastian Schwind, Madlen Jentzsch

Blood Adv (2021) 5 (24): 5584–5587.

https://doi.org/10.1182/bloodadvances.2021005974

Published: 2021

Includes: Supplemental data

Journal Articles

Long-term quality of life of patients with acute promyelocytic leukemia treated with arsenic trioxide vs chemotherapy

Blood Adv (2021) 5 (21): 4370–4379.

https://doi.org/10.1182/bloodadvances.2021004649

Published: 2021

Includes: Supplemental data

Journal Articles

Impact of PTPN11 mutations on clinical outcome analyzed in 1529 patients with acute myeloid leukemia

Blood Adv (2021) 5 (17): 3279–3289.

https://doi.org/10.1182/bloodadvances.2021004631

Published: 2021

Includes: Supplemental data

Journal Articles

A prognostic score including mutation profile and clinical features for patients with CMML undergoing stem cell transplantation

Blood Adv (2021) 5 (6): 1760–1769.

https://doi.org/10.1182/bloodadvances.2020003600

Published: 2021

Includes: Supplemental data

Journal Articles

Development of luspatercept to treat ineffective erythropoiesis

Anne Sophie Kubasch, Pierre Fenaux, Uwe Platzbecker

Blood Adv (2021) 5 (5): 1565–1575.

https://doi.org/10.1182/bloodadvances.2020002177

Published: 2021

Journal Articles

Guideline-based indicators for adult patients with myelodysplastic syndromes

Blood Adv (2020) 4 (16): 4029–4044.

https://doi.org/10.1182/bloodadvances.2020002314

Published: 2020

Includes: Supplemental data

Journal Articles

Prognostic impact of the ELN2017 risk classification in patients with AML receiving allogeneic transplantation

Juliane Grimm, Madlen Jentzsch, Marius Bill, Karoline Goldmann, Julia Schulz, Dietger Niederwieser, Uwe Platzbecker, Sebastian Schwind

Blood Adv (2020) 4 (16): 3864–3874.

https://doi.org/10.1182/bloodadvances.2020001904

Published: 2020

Includes: Supplemental data

Journal Articles

Do next-generation sequencing results drive diagnostic and therapeutic decisions in MDS?

Felicitas Thol, Uwe Platzbecker

Blood Adv (2019) 3 (21): 3449–3453.

https://doi.org/10.1182/bloodadvances.2018022434

Published: 2019

Journal Articles

Enhanced labile plasma iron in hematopoietic stem cell transplanted patients promotes Aspergillus outgrowth

Verena Petzer, Martin Wermke, Piotr Tymoszuk, Dominik Wolf, Markus Seifert, Rıdvan Ovaçin, Sylvia Berger, Dorothea Orth-Höller, Lorin Loacker, Günter Weiss, Hubertus Haas, Uwe Platzbecker, Igor Theurl

Blood Adv (2019) 3 (11): 1695–1700.

https://doi.org/10.1182/bloodadvances.2019000043

Published: 2019

Includes: Supplemental data

Journal Articles

Evaluation of induction chemotherapies after hypomethylating agent failure in myelodysplastic syndromes and acute myeloid leukemia

Brian Ball, Rami S. Komrokji, Lionel Adès, Mikkael A. Sekeres, Amy E. DeZern, Lisa Pleyer, Norbert Vey, Antonio Almeida, Ulrich Germing, Thomas Cluzeau, Uwe Platzbecker, Steven D. Gore, Pierre Fenaux, Thomas Prebet

Blood Adv (2018) 2 (16): 2063–2071.

https://doi.org/10.1182/bloodadvances.2018015529

Published: 2018

Includes: Supplemental data

NARROW

Validation of the Revised 2022 European LeukemiaNet Risk Stratification in Adult Patients with Acute Myeloid Leukemia

Teclistamab impairs detection of BCMA CAR-T cells

Momelotinib long-term safety and survival in myelofibrosis: integrated analysis of phase 3 randomized controlled trials

An agenda to advance research in myelodysplastic syndromes: a TOP 10 priority list from the first international workshop in MDS

Impact of IDH1 and IDH2 mutation detection at diagnosis and in remission in patients with AML receiving allogeneic transplantation

Efficacy and safety of avapritinib in previously treated patients with advanced systemic mastocytosis

Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML

Impact of MRD status in patients with AML undergoing allogeneic stem cell transplantation in the first vs the second remission

Deep sequencing in CD34 + cells from peripheral blood enables sensitive detection of measurable residual disease in AML

Differential impact of IDH1 / 2 mutational subclasses on outcome in adult AML: results from a large multicenter study

The diagnostic red blood cell distribution width as a prognostic factor in acute myeloid leukemia

Long-term quality of life of patients with acute promyelocytic leukemia treated with arsenic trioxide vs chemotherapy

Impact of PTPN11 mutations on clinical outcome analyzed in 1529 patients with acute myeloid leukemia

A prognostic score including mutation profile and clinical features for patients with CMML undergoing stem cell transplantation

Development of luspatercept to treat ineffective erythropoiesis

Guideline-based indicators for adult patients with myelodysplastic syndromes

Prognostic impact of the ELN2017 risk classification in patients with AML receiving allogeneic transplantation

Do next-generation sequencing results drive diagnostic and therapeutic decisions in MDS?

Enhanced labile plasma iron in hematopoietic stem cell transplanted patients promotes Aspergillus outgrowth

Evaluation of induction chemotherapies after hypomethylating agent failure in myelodysplastic syndromes and acute myeloid leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only